An article titled “EHA: Dasatinib gets early edge over imatinib in CML,” published June 14, 2015, misstated the type of cancer treated in the study. The dasatinib/imatinib SPIRIT2 trial is in chronic myeloid leukemia.
An article titled “EHA: Dasatinib gets early edge over imatinib in CML,” published June 14, 2015, misstated the type of cancer treated in the study. The dasatinib/imatinib SPIRIT2 trial is in chronic myeloid leukemia.
AT THE ACR ANNUAL MEETING BOSTON (FRONTLINE MEDICAL NEWS) – Improvements in pain, stiffness, ...
When used with cognitive-behavioral therapy, extended-release mixed amphetamine salts improved outcomes in patients with ...
FROM PEDIATRICS First-time youth tobacco users are turning to e-cigarettes, a survey showed. Researchers ...
